Amy L. Inselman Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Research Biologist
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Amy L. Inselman, a Research Biologist at the National Center for Toxicological Research, studies the effects of various substances and conditions on biological systems, with a particular focus on reproductive health and the development of preclinical models. Her work includes investigating the impact of opioid exposures on mouse fetuses, utilizing MALDI mass spectrometry imaging to identify toxicity markers. Inselman also examines the efficacy of coadministered treatments, such as black cohosh extract and risedronate, on bone health in rat models. She has contributed to discussions on the benefits and limitations of preclinical models for neonatal drug development and the regulation of drugs of abuse. Her scholarship metrics include an h-index of 14, with 47 total publications and 989 total citations. Inselman collaborates with researchers such as Richard D. Beger, E. Ellen Jones, Dustyn A. Barnette, and Sumit Sarkar, all from the National Center for Toxicological Research.
Metrics
- h-index: 14
- Publications: 52
- Citations: 996
Selected Publications
-
A screening strategy for identifying the developmental and reproductive toxicity potential of botanicals (2026)
-
Regulating drugs of abuse to balance advances in research and public health (2026)
-
The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following in utero opioid exposures in mouse fetuses (2024)
-
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model (2024)
-
The benefits, limitations and opportunities of preclinical models for neonatal drug development (2022)
Collaboration Network
Top Collaborators
- The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model
- The incorporation of MALDI mass spectrometry imaging in studies to identify markers of toxicity following in utero opioid exposures in mouse fetuses
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
- The benefits, limitations and opportunities of preclinical models for neonatal drug development
Similar Researchers
Based on overlapping research topics